[Clinical phase II study of TK-117 by Cooperative Study Group. Effects on gastric cancer].
A clinical phase II study of TK-117, one of the derivatives of FUDR, was performed in 18 patients with gastric cancer by our Cooperative Study Group of Cancer Chemotherapy. Fourteen cases were evaluable and 3 of these showed partial response, giving a response rate of 21.4%. Toxic manifestations were experienced in fifteen of 18 cases (83.3%). Gastrointestinal toxicity was major and severe, especially diarrhea, which impeded the continuation of administration. This study revealed the usefulness of TK-117 for gastric cancer, but also the necessity of overcoming its toxicity, especially gastrointestinal complications.
Suzuki
H
H
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D049691:History, Medieval; D006801:Humans; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D005467:Floxuridine; C045214:TK 117